Toulon P, Bardin J M, Blumenfeld N
Laboratoire d'Hématologie, Hôpital Cochin, Paris, France.
Thromb Haemost. 1990 Nov 30;64(3):365-8.
Heparin cofactor II (HCII) is a thrombin inhibitor present in human plasma whose activity is enhanced by heparin. HCII exhibits important homologies with antithrombin III, the main heparin-enhanced thrombin inhibitor. Cases of recurrent thromboembolism have been recently reported in patients with HCII deficiency. Since the use of oral contraceptives (OC) is associated with an increased risk of thrombosis, the study of the plasma levels of HCII was undertaken in women taking contraceptive pills. Plasma HCII levels were found significantly higher in 62 women taking low-estrogen content OC (1.20 +/- 0.28 U/ml) than in 62 age matched women not taking OC (0.94 +/- 0.16 U/ml) or in 62 men (0.96 +/- 0.19 U/ml). Significant correlations between HCII and fibrinogen levels were reported in the three groups. From the pooled data of the two control groups (men and women not taking OC), the normal range for plasma HCII levels was defined to be between 0.60 and 1.30 U/ml (mean +/- 2 SD). Two cases of low HCII levels (less than 0.60 U/ml) were found in the control groups, but none in the group of women taking OC. It is concluded that the use of oral contraceptives is associated with a rise in HCII levels and that the screening for HCII deficiency has to be performed at distance of any OC therapy.
肝素辅因子II(HCII)是一种存在于人体血浆中的凝血酶抑制剂,其活性可被肝素增强。HCII与抗凝血酶III具有重要的同源性,抗凝血酶III是主要的肝素增强型凝血酶抑制剂。最近有报道称,HCII缺乏的患者会出现复发性血栓栓塞病例。由于口服避孕药(OC)的使用与血栓形成风险增加有关,因此对服用避孕药的女性进行了血浆HCII水平的研究。发现62名服用低雌激素含量OC的女性的血浆HCII水平(1.20 +/- 0.28 U/ml)显著高于62名年龄匹配的未服用OC的女性(0.94 +/- 0.16 U/ml)或62名男性(0.96 +/- 0.19 U/ml)。三组中均报道了HCII与纤维蛋白原水平之间存在显著相关性。根据两个对照组(男性和未服用OC的女性)的汇总数据,血浆HCII水平的正常范围被定义为0.60至1.30 U/ml(平均值 +/- 2标准差)。在对照组中发现了2例低HCII水平(低于0.60 U/ml)的病例,但在服用OC的女性组中未发现。结论是,口服避孕药的使用与HCII水平升高有关,并且必须在停止任何OC治疗后进行HCII缺乏症的筛查。